Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly Puts Down $200m To Use Dicerna's RNAi Platform For Metabolic, Neurological Diseases

Oct 29 2018

• By Mandy Jackson

businessman and businesswoman are shaking hands and exchanging folder after agreement was reached

Related Content

Appointments: Lilly, Kiadis, Pliant, Alma, NeuroVia and Nektar Therapeutics

Sep 29 2017

With Dicerna's NASH Asset, Boehringer Found What It Was Looking For

Nov 02 2017

Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO

Jul 28 2016

Finance Watch: Opko's Stock Halted As Nasdaq Awaits An Explanation For SEC Pump-And-Dump Lawsuit

Sep 12 2018

Related Companies

Dicerna Pharmaceuticals, Inc.

Eli Lilly and Company

Alexion Pharmaceuticals Inc.

Boehringer Ingelheim GmbH

Additional Topics

Deals Business Strategies Financing Companies Commercial BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window